Does reduced SULT2A1 activity lower circulating DHEA-S?

The sulfotransferase enzyme SULT2A1 is the primary driver of the biochemical conversion of dehydroepiandrosterone (DHEA) into its sulfated reservoir form, DHEA-S. This process plays a vital role in maintaining the systemic androgen balance, which naturally shifts with age.

Mechanistic pathways of DHEA sulfation

• Enzymatic kinetics: SULT2A1 mediates the transfer of a sulfonyl group to DHEA. Functional coding polymorphisms within the gene alter the enzyme's substrate affinity ($K_m$) and maximum velocity ($V_{max}$), directly regulating overall catalytic output.
• Cofactor reliance: The sulfoconjugation process is biochemically constrained by the availability of the active sulfate donor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS). SULT2A1 requires direct interaction with PAPS synthase 2 (PAPSS2) to supply this donor; genetic mutations in PAPSS2 can result in near-absent DHEA-S synthesis.

Genetic determinants of circulating DHEA-S

• Gene dosage and haplotypes: Copy-number variations (CNVs) in the SULT2A1 gene exert strong gene-dosage effects, where fewer gene copies lead to significantly reduced sulfation output. In males, specific coding haplotypes like the SULT2A13* genotype lead to a significantly decreased DHEA-S to DHEA ratio, highlighting impaired conversion efficiency.
• Regulatory polymorphisms: Common non-coding single nucleotide polymorphisms (SNPs), such as rs182420 and rs2637125, demonstrate modest, age-dependent, and cohort-specific associations with lower circulating DHEA-S levels.

Bottom line

• Reduced SULT2A1 activity—whether driven by lower gene copy numbers, the SULT2A13* haplotype, regulatory SNPs, or restricted PAPS cofactor supply—directly compromises sulfoconjugation efficiency, lowering systemic circulating DHEA-S availability.